CN106456645B - 用于放射性标记的方法和试剂 - Google Patents

用于放射性标记的方法和试剂 Download PDF

Info

Publication number
CN106456645B
CN106456645B CN201480076193.7A CN201480076193A CN106456645B CN 106456645 B CN106456645 B CN 106456645B CN 201480076193 A CN201480076193 A CN 201480076193A CN 106456645 B CN106456645 B CN 106456645B
Authority
CN
China
Prior art keywords
compound
group
formula
nitrogen
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480076193.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106456645A (zh
Inventor
斯特凡·O·奥基亚讷
纳加沃劳基肖尔·皮勒瑟蒂
托尼·塔尔多内
加芙列拉·基奥西斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN106456645A publication Critical patent/CN106456645A/zh
Application granted granted Critical
Publication of CN106456645B publication Critical patent/CN106456645B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201480076193.7A 2013-12-23 2014-12-23 用于放射性标记的方法和试剂 Expired - Fee Related CN106456645B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361919901P 2013-12-23 2013-12-23
US61/919,901 2013-12-23
PCT/US2014/072090 WO2015138039A1 (en) 2013-12-23 2014-12-23 Methods and reagents for radiolabeling

Publications (2)

Publication Number Publication Date
CN106456645A CN106456645A (zh) 2017-02-22
CN106456645B true CN106456645B (zh) 2021-03-23

Family

ID=54072256

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480076193.7A Expired - Fee Related CN106456645B (zh) 2013-12-23 2014-12-23 用于放射性标记的方法和试剂

Country Status (13)

Country Link
US (3) US9994573B2 (enExample)
EP (1) EP3086792B1 (enExample)
JP (1) JP6491214B2 (enExample)
KR (1) KR102325454B1 (enExample)
CN (1) CN106456645B (enExample)
AU (1) AU2014386214B2 (enExample)
BR (1) BR112016014758A8 (enExample)
CA (1) CA2934850C (enExample)
IL (1) IL246403B (enExample)
MX (1) MX2016008418A (enExample)
RU (1) RU2016128528A (enExample)
TW (1) TWI673279B (enExample)
WO (1) WO2015138039A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138039A1 (en) 2013-12-23 2015-09-17 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
MX387627B (es) * 2014-09-17 2025-03-18 Memorial Sloan Kettering Cancer Center Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia
WO2017002196A1 (ja) * 2015-06-30 2017-01-05 株式会社日立国際電気 整合器及び整合方法
KR102175125B1 (ko) * 2018-12-28 2020-11-05 울산과학기술원 미토콘드리아 표적 Hsp90 억제제 기반 화합물 및 이를 포함하는 광역학 치료를 위한 약학적 조성물
WO2022182731A1 (en) * 2021-02-24 2022-09-01 Samus Therapeutics, Inc. Sn-labeling and radiolabeling of epichaperome inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084030A3 (en) * 2005-02-01 2007-01-25 Sloan Kettering Inst Cancer Small-molecule hsp90 inhibitors
WO2012138894A1 (en) * 2011-04-05 2012-10-11 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
WO2013009657A1 (en) * 2011-07-08 2013-01-17 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US20070178537A1 (en) * 2003-06-30 2007-08-02 Sloan-Kettering Institute For Cancer Research Assays for detection of bioactive compounds that interact with heat shock protein 90
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2007134298A2 (en) 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
WO2008005937A2 (en) 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
KR101313804B1 (ko) 2007-03-20 2013-10-01 쿠리스 인코퍼레이션 Ｈｓｐ９０ 억제제로서의 융합된 아미노 피리딘
NZ586129A (en) 2007-11-14 2012-06-29 Myrexis Inc Therapeutic compounds and their use in treating diseases and disorders
JP5941407B2 (ja) 2009-10-07 2016-06-29 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害剤
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
BR112013027448A2 (pt) 2011-04-28 2020-09-01 Sloan-Kettering Institute For Cancer Research terapia de combinação com hsp90
EP2972394A4 (en) * 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer HSP90-DESIGNING AND THERAPY
SG11201601542SA (en) 2013-08-16 2016-04-28 Sloan Kettering Inst Cancer Selective grp94 inhibitors and uses thereof
WO2015138039A1 (en) 2013-12-23 2015-09-17 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
MX387627B (es) 2014-09-17 2025-03-18 Memorial Sloan Kettering Cancer Center Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia
US20180280397A1 (en) 2015-10-05 2018-10-04 Memorial Sloan Kettering Cancer Center Rational combination therapy for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084030A3 (en) * 2005-02-01 2007-01-25 Sloan Kettering Inst Cancer Small-molecule hsp90 inhibitors
WO2012138894A1 (en) * 2011-04-05 2012-10-11 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
WO2013009657A1 (en) * 2011-07-08 2013-01-17 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors

Also Published As

Publication number Publication date
EP3086792B1 (en) 2022-10-12
CA2934850C (en) 2022-12-06
BR112016014758A8 (pt) 2020-06-02
US20200017502A1 (en) 2020-01-16
IL246403B (en) 2020-08-31
US20170029426A1 (en) 2017-02-02
TWI673279B (zh) 2019-10-01
RU2016128528A (ru) 2018-01-30
BR112016014758A2 (enExample) 2017-08-08
AU2014386214B2 (en) 2020-05-21
JP6491214B2 (ja) 2019-03-27
EP3086792A4 (en) 2017-05-24
US20180251461A1 (en) 2018-09-06
MX2016008418A (es) 2017-01-11
CN106456645A (zh) 2017-02-22
AU2014386214A1 (en) 2016-07-14
WO2015138039A1 (en) 2015-09-17
EP3086792A1 (en) 2016-11-02
KR102325454B1 (ko) 2021-11-16
US9994573B2 (en) 2018-06-12
CA2934850A1 (en) 2015-09-17
US10329293B2 (en) 2019-06-25
KR20160101186A (ko) 2016-08-24
US10793570B2 (en) 2020-10-06
IL246403A0 (en) 2016-08-31
TW201609773A (zh) 2016-03-16
JP2017502039A (ja) 2017-01-19

Similar Documents

Publication Publication Date Title
US10793570B2 (en) Methods and reagents for radiolabeling
CN113666923A (zh) 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
TW202311260A (zh) 含有亞磺醯亞胺基的atr抑制劑化合物
MX2015002695A (es) Derivados biciclicos fusionados de sulfamoilo y su uso como medicamentos para el tratamiento de la hepatitis b.
EA020885B1 (ru) Ингибиторы протеинкиназы и их применение
EP3398598B1 (en) Sulfonamide derivative and preparation method and use thereof
CN103570722A (zh) 稠环哒嗪酮类化合物及其制备方法和用途
CN116120296A (zh) 一种多环化合物、包含其的药物组合物、其制备方法及其用途
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
CN116789641A (zh) 二氢异喹啉类化合物及其医药用途
CN116768870A (zh) 具有苄氧基芳基醚结构的化合物及其制备方法和用途
TWI843229B (zh) 新穎蛋白殼組裝抑制劑
CN113939290A (zh) Abhd12抑制剂及其制造和使用方法
CN116783198B (zh) 螺环jak抑制剂、含其的药物组合物及其应用
EP4357343A1 (en) Rna-binding molecules with a small core scaffold (r-score) and uses thereof
CA3285927A1 (en) Kif18a inhibitor
HK40105472A (zh) 用作cdk4激酶抑制剂的化合物及其应用
WO2016034637A1 (fr) Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques comme inhibiteurs de la ftl3 et jak
CN113461700A (zh) 一种氧气促进的去芳香化反应在构建螺环二烯酮骨架中的应用
CN121735909A (zh) 多价分子胶类化合物及其制备和应用
CN121318828A (zh) 一种炎症小体抑制剂及其应用
CN121293164A (zh) 一种小分子化合物及其制备方法与在抗癌药物中的应用
JP2020186182A (ja) 標的蛋白質分解誘導化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210323